About Preval Health
The gap between evidence and access.
The science of lipid management has advanced remarkably. The delivery of that science to patients has not kept pace. Preval Health exists to close that gap.
Our Mission
Advanced lipid management, accessible.
Cardiovascular disease remains the leading cause of death worldwide. Yet the therapies that can dramatically reduce risk (high-intensity statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, inclisiran) are prescribed far less than the evidence supports. Fewer than one in five high-risk patients reach guideline-recommended LDL-C levels.
This is not a knowledge problem. The landmark trials are published. The guidelines are written. The medications are FDA-approved. What’s missing is a clinical service designed to put all of it together for the patient: to prescribe aggressively, titrate carefully, monitor advanced biomarkers, and stay with the patient until they reach their target.
Preval Health was built to be that service.
The Problem
Knowledge exists. Access does not.
Most primary care physicians manage large panels with limited time per visit. Lipid management often ends at a standard statin dose. Advanced therapies, combination protocols, and biomarkers like Lp(a) and apoB rarely make it into the conversation. Not because physicians don’t care, but because the system doesn’t give them the time or infrastructure to go further.
In the absence of accessible expertise, patients turn to what they can find: social media, wellness influencers, and online content that often confuses more than it clarifies. Some of it is well-intentioned. Some of it is not. Either way, it is no substitute for a cardiologist who reads the trials, understands the pharmacology, and takes responsibility for the outcome.
We believe patients deserve better than noise. They deserve a clinician who will look at their numbers, prescribe what the evidence supports, and follow through.
50%
reduction in cardiac events with aggressive LDL-C lowering
<20%
of high-risk patients currently reach guideline LDL-C targets
4+
classes of lipid-lowering therapy now FDA-approved
60%
LDL-C reduction achieved in a single gene-editing infusion (preclinical)
Founders
Two cardiologists. One conviction.
Kaustubh Dabhadkar, MD, MPH, FACC
Co-Founder
Board-certified preventive cardiologist practicing in Charlotte, North Carolina. Dr. Dabhadkar completed his internal medicine residency and Master of Public Health in Epidemiology at Emory University, followed by a fellowship in cardiovascular disease at Brown University.
He serves as an adjunct assistant professor at the University of North Carolina and is a member of the American College of Cardiology’s Leadership Council on Preventive Cardiology. His research in cardiovascular epidemiology and prevention has been cited over 77,000 times.
His focus is on translating population-level evidence into individualized treatment, reaching the patients who fall through the cracks of a system that knows what to do but too often does not do it.
Kapil Yadav, MD, FACC, RPVI
Co-Founder
Interventional cardiologist and Associate Professor at the University of Arkansas for Medical Sciences, where he leads the Nuclear Cardiology and Vascular Medicine Program. Dr. Yadav completed his internal medicine residency at Cook County Hospital in Chicago, a cardiovascular disease fellowship at Tulane University, and an interventional and structural cardiology fellowship at the University of Arizona.
Board-certified in cardiovascular disease, interventional cardiology, nuclear cardiology, and echocardiography, he brings the procedural perspective: an understanding of what happens when prevention fails and patients end up in the catheterization lab.
His conviction is simple: many of those procedures could have been prevented with earlier, more aggressive lipid management.
Built by physicians. Grounded in evidence.
We are not selling supplements or wellness advice. We prescribe FDA-approved medications, guided by the same trials we publish in.
Join the Waitlist